Retatrutide is a next-generation triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. It demonstrates superior weight loss efficacy compared to dual or single agonists, making it one of the most potent peptides in development for metabolic health, obesity management, and cardiometabolic disease.
Key Benefits
- Significant body weight reduction (up to 24% in clinical trials)
- Improved insulin sensitivity and glycemic control
- Reduction in liver fat and visceral adiposity
- Favorable cardiovascular risk profile
- Appetite suppression and reduced caloric intake
